Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MME | P08473 | 2/20 | 0.50 |
| ▸ | ACE | P12821 | 2/20 | 0.50 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 3/20 | 0.47 |
| ▸ | MMP8 | P22894 | 2/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | CPA1 | P15085 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.46 |
| ▸ | MMP14 | P50281 | 1/20 | 0.46 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3656658 | 0.91 | TACR1 (0.56) | TACR1MMEACEMMP9MMP8 | |
| SCHEMBL3660470 | 0.91 | TACR1 (0.53) | TACR1MEN1KMT2AMMEACE | |
| SCHEMBL3662925 | 0.91 | TACR1 (0.51) | TACR1MEN1KMT2AMMEACE | |
| SCHEMBL3653219 | 0.89 | MME (0.61) | TACR1MEN1KMT2AMMEACE | |
| SCHEMBL3654101 | 0.89 | CTSS (0.53) | TACR1MMEACEMMP9MMP8 | |
| SCHEMBL3662917 | 0.89 | TACR1 (0.52) | TACR1MEN1KMT2AMMEACE | |
| SCHEMBL3657160 | 0.87 | FNTA (0.51) | TACR1MEN1KMT2AMMEACE | |
| SCHEMBL3654406 | 0.87 | MME (0.51) | TACR1MMEACEMMP9MMP8 | |
| SCHEMBL3663836 | 0.86 | FNTA (0.50) | TACR1MEN1KMT2AMMEACE | |
| SCHEMBL11027962 | 0.82 | TACR1 (0.69) | TACR1MEN1KMT2AMMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9364424-B2 | Topical cosmetic skin lightening compositions and methods of use thereof | STIEFEL LABORATORIES, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20160074315-A1 | TOPICAL COSMETIC SKIN LIGHTENING COMPOSITIONS AND METHODS OF USE THEREOF | STIEFEL LABORATORIES, INC. | 2016-03-17 | — | — | US | disclosed |
| EP-2219600-A1 | TOPICAL COSMETIC SKIN LIGHTENING COMPOSITIONS AND METHODS OF USE THEREOF | STIEFEL LABORATORIES, INC. (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009067095-A1 | TOPICAL COSMETIC SKIN LIGHTENING COMPOSITIONS AND METHODS OF USE THEREOF | STIEFEL LABORATORIES, INC. (US) | 2009-05-28 | — | — | WO | disclosed |
| EP-1604647-B1 | Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof | CHISSO CORP (JP) | 2008-05-07 | — | — | EP | disclosed |
| US-20060018867-A1 | Cosmetic composition and production thereof | ICHIMARU PHARCOS CO., LTD | 2006-01-26 | — | — | US | disclosed |
| EP-1604647-A1 | Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof | Ichimaru Pharcos Co., Ltd. (JP) | 2005-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060018867-A1 | Cosmetic composition and production thereof | CUTA, PARG, TYR | TACR1 3585/4885MEN1 1028/4885KMT2A 847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.